Pharmaron Beijing Co Ltd (SHE:300759) — Market Cap & Net Worth
Market Cap & Net Worth: Pharmaron Beijing Co Ltd (300759)
Pharmaron Beijing Co Ltd (SHE:300759) has a market capitalization of $5.08 Billion (CN¥34.69 Billion) as of June 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #3564 globally and #532 in its home market, demonstrating a -7.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pharmaron Beijing Co Ltd's stock price CN¥23.49 by its total outstanding shares 1476658400 (1.48 Billion). Review Pharmaron Beijing Co Ltd debt and liabilities to assess the company's total debt and financial obligations.
Pharmaron Beijing Co Ltd Market Cap History: 2019 to 2026
Pharmaron Beijing Co Ltd's market capitalization history from 2019 to 2026. Data shows growth from $4.80 Billion to $5.08 Billion (24.32% CAGR).
Index Memberships
Pharmaron Beijing Co Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ChiNext
CNT
|
$1.45 Trillion | 0.35% | #52 of 100 |
Weight: Pharmaron Beijing Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pharmaron Beijing Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pharmaron Beijing Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.45x
Pharmaron Beijing Co Ltd's market cap is 0.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.10x
Pharmaron Beijing Co Ltd's market cap is 3.10 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $4.80 Billion | $3.76 Billion | $547.19 Million | 1.28x | 8.78x |
| 2020 | $11.23 Billion | $5.13 Billion | $1.17 Billion | 2.19x | 9.58x |
| 2021 | $13.20 Billion | $7.44 Billion | $1.66 Billion | 1.77x | 7.95x |
| 2022 | $9.58 Billion | $10.27 Billion | $1.37 Billion | 0.93x | 6.97x |
| 2023 | $6.20 Billion | $11.54 Billion | $1.60 Billion | 0.54x | 3.87x |
| 2024 | $5.55 Billion | $12.28 Billion | $1.79 Billion | 0.45x | 3.10x |
Competitor Companies of 300759 by Market Capitalization
Companies near Pharmaron Beijing Co Ltd in the global market cap rankings as of June 4, 2026.
Key companies related to Pharmaron Beijing Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #227 globally with a market cap of $108.72 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #428 globally with a market cap of $63.77 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #581 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #602 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #227 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $108.72 Billion | $428.34 |
| #428 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.77 Billion | $618.95 |
| #581 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #602 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
Pharmaron Beijing Co Ltd Historical Marketcap From 2019 to 2026
Between 2019 and today, Pharmaron Beijing Co Ltd's market cap moved from $4.80 Billion to $ 5.08 Billion, with a yearly change of 24.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥5.08 Billion | -17.38% |
| 2025 | CN¥6.14 Billion | +10.62% |
| 2024 | CN¥5.55 Billion | -10.39% |
| 2023 | CN¥6.20 Billion | -35.32% |
| 2022 | CN¥9.58 Billion | -27.41% |
| 2021 | CN¥13.20 Billion | +17.50% |
| 2020 | CN¥11.23 Billion | +133.95% |
| 2019 | CN¥4.80 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 4th, 2026 the market cap of Pharmaron Beijing Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.08 Billion USD |
| MoneyControl | $5.08 Billion USD |
| MarketWatch | $5.08 Billion USD |
| marketcap.company | $5.08 Billion USD |
| Reuters | $5.08 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pharmaron Beijing Co Ltd
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy … Read more